...
首页> 外文期刊>European journal of human genetics: EJHG >Association of modifiers and other genetic factors explain Marfan syndrome clinical variability.
【24h】

Association of modifiers and other genetic factors explain Marfan syndrome clinical variability.

机译:改性剂和其他遗传因素的协会解释了Marfan综合征的临床变异性。

获取原文
获取原文并翻译 | 示例
           

摘要

Marfan syndrome (MFS) is a rare autosomal dominant connective tissue disorder related to variants in the FBN1 gene. Prognosis is related to aortic risk of dissection following aneurysm. MFS clinical variability is notable, for age of onset as well as severity and number of clinical manifestations. To identify genetic modifiers, we combined genome-wide approaches in 1070 clinically well-characterized FBN1 disease-causing variant carriers: (1) an FBN1 eQTL analysis in 80 fibroblasts of FBN1 stop variant carriers, (2) a linkage analysis, (3) a kinship matrix association study in 14 clinically concordant and discordant sib-pairs, (4) a genome-wide association study and (5) a whole exome sequencing in 98 extreme phenotype samples.Three genetic mechanisms of variability were found. A new genotype/phenotype correlation with an excess of loss-of-cysteine variants (P?=?0.004) in severely affected subjects. A second pathogenic event in another thoracic aortic aneurysm gene or the COL4A1 gene (known to be involved in cerebral aneurysm) was found in nine individuals. A polygenic model involving at least nine modifier loci (named gMod-M1-9) was observed through cross-mapping of results. Notably, gMod-M2 which co-localizes with PRKG1, in which activating variants have already been described in thoracic aortic aneurysm, and gMod-M3 co-localized with a metalloprotease (proteins of extra-cellular matrix regulation) cluster. Our results represent a major advance in understanding the complex genetic architecture of MFS and provide the first steps toward prediction of clinical evolution.
机译:Marfan综合征(MFS)是与FBN1基因中的变体有关的稀有常染色体显性结缔组织障碍。预后与动脉瘤后解剖的主动脉风险有关。 MFS临床变异是值得注意的,因为发病年龄以及临床表现的严重程度和数量。为了鉴定遗传调节剂,我们在1070临床上良好特征的FBN1疾病变异载体中组合基因组方法:(1)FBN1止动变体载体的80个成纤维细胞中的FBN1 EQTL分析,(2)连锁分析,(3)在14个临床上的临床上和不间断的SIB对中进行亲属矩阵协会研究,(4)一个基因组 - 宽的协会研究和(5)在98个极端表型样品中的整个外部测序。发现了可变性的基因遗传机制。一种新的基因型/表型与过量的半胱氨酸损失变体(P?= 0.004)在严重受影响的受试者中。在九个个体中发现另一种胸主动脉瘤基因或COL4A1基因(已知参与脑动脉瘤的COL4A1基因的第二致病事件。通过对结果的交叉映射观察涉及至少九种改性基因座(名为GMOD-M1-9)的多种基因模型。值得注意的是,用PRKG1共定出的GMOD-M2,其中已经在胸主动脉瘤中描述了激活变​​体,并用金属蛋白酶(外细胞基质调节的蛋白质)簇共定出的GMOD-M3。我们的业绩代表了了解MFS复杂的遗传架构,并提供临床演变预测的第一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号